Essential thrombocytosis historical perspective: Difference between revisions
No edit summary |
No edit summary |
||
| Line 30: | Line 30: | ||
| doi = 10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2 | | doi = 10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2 | ||
| pmid = 16879015 | | pmid = 16879015 | ||
}}</ref> Later on, | }}</ref> Later on, essential thrombocytosis was grouped under myeloproliferative disorders along with chronic myelogenous leukemia ([[CML]]), [[polycythemia vera]] (PV), and chronic idiopathic myelofibrosis(CIMF). | ||
==References== | ==References== | ||
Revision as of 16:31, 12 November 2015
|
Essential thrombocytosis Microchapters |
|
Differentiating Essential thrombocytosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Essential thrombocytosis historical perspective On the Web |
|
American Roentgen Ray Society Images of Essential thrombocytosis historical perspective |
|
Risk calculators and risk factors for Essential thrombocytosis historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]
Overview
Essential thrombocytosis was first clearly described by its synonym "Hemorrhagic thrombocythemia" by two Austrian pathologists Emil Epstein and Alfred Goedel in the year 1934.[1]
Historical perspective
Essential thrombocytosis was first clearly described by its synonym "Hemorrhagic thrombocythemia" by two Austrian pathologists Emil Epstein and Alfred Goedel in the year 1934.[1] Later on, essential thrombocytosis was grouped under myeloproliferative disorders along with chronic myelogenous leukemia (CML), polycythemia vera (PV), and chronic idiopathic myelofibrosis(CIMF).
References
- ↑ 1.0 1.1 Steven Sanchez & April Ewton (2006). "Essential thrombocythemia: a review of diagnostic and pathologic features". Archives of pathology & laboratory medicine. 130 (8): 1144–1150. doi:10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2. PMID 16879015. Unknown parameter
|month=ignored (help)